RZLT RSI Chart
Last 7 days
-12.4%
Last 30 days
-19.1%
Last 90 days
94.1%
Trailing 12 Months
25.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 5.3M | 0 | 0 | 0 |
2023 | 2.8M | 4.2M | 5.2M | 5.7M |
2022 | 75.0K | 81.0K | 480.0K | 1.3M |
2021 | 725.0K | 63.0K | 0 | 69.0K |
2020 | 1.7M | 1.2M | 1.2M | 1.4M |
2019 | 745.3K | 1.3M | 1.6M | 1.7M |
2018 | 1.2M | 762.0K | 660.3K | 532.5K |
2017 | 661.1K | 1.1M | 1.2M | 1.3M |
2016 | 495.6K | 442.0K | 466.1K | 489.8K |
2015 | 682.7K | 539.5K | 378.0K | 461.1K |
2014 | 502.2K | 684.1K | 886.4K | 838.7K |
2013 | 565.4K | 634.1K | 597.8K | 540.1K |
2012 | 261.7K | 0 | 362.9K | 464.2K |
2011 | 0 | 0 | 0 | 160.5K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 28, 2024 | roberts brian kenneth | bought | 1,275 | 2.55 | 500 | chief medical officer |
Mar 15, 2024 | evans daron | bought | 33,830 | 1.6915 | 20,000 | cfo |
Mar 14, 2024 | roberts brian kenneth | bought | 18,800 | 1.88 | 10,000 | chief medical officer |
Mar 08, 2024 | evans daron | bought | 96,345 | 1.9269 | 50,000 | cfo |
Mar 07, 2024 | roberts brian kenneth | bought | 925 | 1.85 | 500 | chief medical officer |
Mar 07, 2024 | kim young-jin | bought | 69,859 | 1.9138 | 36,503 | - |
Feb 26, 2024 | elam nevan c | bought | 8,400 | 1.68 | 5,000 | ceo |
Feb 26, 2024 | roberts brian kenneth | bought | 3,400 | 1.7 | 2,000 | chief medical officer |
Feb 23, 2024 | roberts brian kenneth | bought | 10,140 | 1.69 | 6,000 | chief medical officer |
Which funds bought or sold RZLT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | Nantahala Capital Management, LLC | reduced | -1.71 | 4,656,170 | 7,708,520 | 0.44% |
May 15, 2024 | Blackstone Inc. | unchanged | - | 2,394,940 | 3,921,090 | 0.02% |
May 15, 2024 | CITADEL ADVISORS LLC | added | 14.97 | 672,029 | 1,015,980 | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
May 15, 2024 | BVF INC/IL | unchanged | - | 297,194 | 486,578 | 0.01% |
May 15, 2024 | OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | added | 4.16 | 999,910 | 1,596,960 | 0.11% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | unchanged | - | 983,858 | 1,610,810 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 14.79 | 35,249 | 53,331 | -% |
May 15, 2024 | CAXTON CORP | unchanged | - | 2,054,290 | 3,363,370 | 19.16% |
May 15, 2024 | Stonepine Capital Management, LLC | reduced | -95.61 | -2,438,120 | 309,771 | 0.25% |
Unveiling Rezolute, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Rezolute, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Rezolute, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -13.9% | 1,122 | 1,303 | 1,404 | 1,475 | 1,484 | 849 | 400 | 67.00 | - | 13.00 | 1.00 | 241 | 481 | 370 | 217 | 319 | 273 | 360 | 711 | 394 | 86.00 |
Operating Expenses | 6.7% | 16,213 | 15,194 | 15,914 | 14,238 | 17,142 | 14,392 | 10,218 | 11,300 | 10,754 | 12,149 | 6,636 | 5,483 | 7,152 | 3,623 | 3,552 | 5,070 | 6,720 | 5,179 | 3,184 | 17,037 | 3,161 |
S&GA Expenses | -100.0% | - | 3,155 | 3,700 | 3,305 | 2,911 | 3,447 | 2,514 | 2,726 | 2,068 | 2,697 | 2,247 | 1,725 | 2,656 | 1,279 | 1,107 | 1,337 | 1,682 | 1,945 | 1,511 | 1,926 | 1,773 |
R&D Expenses | 3.0% | 12,401 | 12,039 | 12,214 | 10,933 | 14,231 | 10,945 | 7,704 | 8,574 | 8,686 | 9,452 | 4,389 | 3,758 | 4,496 | 2,344 | 2,445 | 3,733 | 5,038 | 3,234 | 1,718 | 15,122 | 1,309 |
Interest Expenses | - | - | - | - | - | - | - | - | 476 | 331 | 340 | - | - | - | - | - | - | - | - | 3,507 | 43.00 | 1,288 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -22.6% | -17,050 | -13,909 | -14,524 | -12,741 | -15,672 | -13,556 | -9,831 | -9,423 | -11,208 | -12,593 | -6,490 | -3,695 | -7,097 | -3,620 | -3,547 | -5,040 | -6,666 | -5,080 | -3,147 | -19,772 | -4,162 |
Net Income Margin | -9.4% | -10.98* | -10.03* | -10.84* | -12.31* | -17.32* | -33.45* | -89.70* | -506.91* | -508.36* | -443.68* | -331.78* | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -17.1% | -15,241 | -13,020 | -10,585 | -11,400 | -18,018 | -7,576 | -7,659 | -12,110 | -13,968 | -7,197 | -5,230 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -14.1% | 88.00 | 102 | 113 | 124 | 134 | 150 | 156 | 152 | 70.00 | 83.00 | 39.00 | 43.00 | 33.00 | 39.00 | 7.00 | 11.00 | 15.00 | 21.00 | 27.00 | 12.00 | 15.00 |
Current Assets | -14.4% | 82.00 | 96.00 | 103 | 105 | 106 | 148 | 156 | 152 | 64.00 | 78.00 | 38.00 | 42.00 | 32.00 | 38.00 | 7.00 | 11.00 | 14.00 | 20.00 | 26.00 | 12.00 | 15.00 |
Cash Equivalents | -52.6% | 6.00 | 13.00 | 8.00 | 16.00 | 34.00 | 147 | 154 | 150 | 63.00 | 82.00 | 37.00 | 41.00 | 32.00 | 38.00 | 6.00 | 10.00 | 14.00 | 18.00 | 22.00 | 38.00 | 15.00 |
Net PPE | -7.6% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 62.3% | 17.00 | 10.00 | 9.00 | 8.00 | 7.00 | 9.00 | 3.00 | 3.00 | 18.00 | 21.00 | 17.00 | 17.00 | 4.00 | 3.00 | 3.00 | 4.00 | 4.00 | 6.00 | 6.00 | 11.00 | 11.00 |
Current Liabilities | -12.5% | 7.00 | 8.00 | 7.00 | 5.00 | 4.00 | 6.00 | 2.00 | 2.00 | 3.00 | 6.00 | 3.00 | 2.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 6.00 | 6.00 | 8.00 | 7.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | 14.00 | 14.00 | 14.00 | 14.00 | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -22.7% | 71.00 | 92.00 | 104 | 116 | 127 | 141 | 153 | 149 | 52.00 | 62.00 | 22.00 | 26.00 | 29.00 | 36.00 | 4.00 | 7.00 | 10.00 | 15.00 | 21.00 | 2.00 | 5.00 |
Retained Earnings | -5.9% | -306 | -289 | -275 | -260 | -248 | -232 | -219 | -209 | -199 | -188 | -175 | -168 | -161 | -157 | -150 | -147 | -143 | -138 | -131 | -126 | -123 |
Additional Paid-In Capital | -1.0% | 377 | 381 | 379 | 377 | 376 | 374 | 372 | 359 | 252 | 251 | 198 | 194 | 191 | 194 | 155 | 155 | 154 | 153 | 152 | 129 | 97.00 |
Shares Outstanding | 1.3% | 40.00 | 40.00 | 37.00 | 37.00 | 37.00 | 51.00 | 51.00 | 34.00 | 14.00 | 16.00 | 9.00 | 8.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | 64.00 | - | - | - | 61.00 | - | - | - | 76.00 | - | - | - | 13.00 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -17.1% | -15,241 | -13,020 | -10,585 | -11,400 | -18,018 | -7,493 | -7,589 | -12,110 | -13,968 | -7,197 | -6,341 | -5,230 | -5,397 | -6,263 | -3,551 | -4,078 | -5,679 | -5,482 | -8,929 | -3,765 | -8,456 |
Share Based Compensation | 3.6% | 1,903 | 1,837 | 1,849 | 1,803 | 1,855 | 1,731 | 1,879 | 984 | 850 | 1,009 | 842 | 1,660 | 530 | 1,141 | 634 | 583 | 675 | 665 | 1,394 | 247 | 695 |
Cashflow From Investing | -51.2% | 8,670 | 17,760 | 2,606 | -6,357 | -94,954 | -83.00 | -70.00 | - | - | - | - | - | - | - | - | - | - | - | - | -6.00 | 42.00 |
Cashflow From Financing | -Infinity% | -3.00 | - | - | - | - | - | 11,571 | 94,104 | -19.00 | 52,308 | 2,586 | 14,288 | -214 | 37,459 | - | - | - | -21.00 | 22,571 | - | 23,500 |
Buy Backs | - | 5,700 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||||
Research and development | $ 12,401 | $ 14,231 | $ 36,654 | $ 32,880 |
General and administrative | 3,812 | 2,911 | 10,667 | 8,872 |
Total operating expenses | 16,213 | 17,142 | 47,321 | 41,752 |
Operating loss | (16,213) | (17,142) | (47,321) | (41,752) |
Non-operating income (expense): | ||||
Interest and other income, net | 1,122 | 1,484 | 3,829 | 2,733 |
Loss from change in fair value of derivative liabilities | (1,959) | (14) | (1,991) | (40) |
Total non-operating income (expense), net | (837) | 1,470 | 1,838 | 2,693 |
Net loss | (17,050) | (15,672) | (45,483) | (39,059) |
Other comprehensive income (loss): | ||||
Net unrealized gain (loss) on available-for-sale marketable debt securities | (30) | (132) | 273 | (132) |
Comprehensive loss | $ (17,080) | $ (15,804) | $ (45,210) | $ (39,191) |
Net loss per common share - basic (in dollars per share) | $ (0.34) | $ (0.30) | $ (0.89) | $ (0.76) |
Net loss per common share - diluted (in dollars per share) | $ (0.34) | $ (0.30) | $ (0.89) | $ (0.76) |
Weighted average number of common shares outstanding - basic (in shares) | 50,811 | 51,409 | 51,212 | 51,113 |
Weighted average number of common shares outstanding - diluted (in shares) | 50,811 | 51,409 | 51,212 | 51,113 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Jun. 30, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,930 | $ 16,036 |
Investments in marketable debt securities | 74,092 | 85,860 |
Prepaid expenses and other | 2,188 | 3,014 |
Total current assets | 82,210 | 104,910 |
Long-term assets: | ||
Investments in marketable debt securities | 1,573 | 16,470 |
Right-of-use assets | 2,006 | 2,054 |
Property and equipment, net | 110 | 139 |
Deposits and other | 1,838 | 148 |
Total assets | 87,737 | 123,721 |
Current liabilities: | ||
Accounts payable | 3,499 | 3,269 |
Accrued liabilities: | ||
Accrued clinical and other | 2,027 | 507 |
Compensation and benefits | 879 | 883 |
Current portion of operating lease liabilities | 552 | 541 |
Total current liabilities | 6,957 | 5,200 |
Long term liabilities: | ||
Operating lease liabilities, net of current portion | 1,819 | 1,937 |
Warrant derivative liability | 7,647 | |
Embedded derivative liability | 453 | 412 |
Total liabilities | 16,876 | 7,549 |
Commitments and contingencies (Notes 5, 9 and 10) | ||
Shareholders' equity: | ||
Preferred stock, $0.001 par value; 400 shares authorized; no shares issued and outstanding | ||
Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 40,132 and 36,827 shares as of March 31, 2024 and June 30, 2023, respectively | 40 | 37 |
Additional paid-in capital | 377,367 | 377,471 |
Accumulated other comprehensive loss | (78) | (351) |
Accumulated deficit | (306,468) | (260,985) |
Total shareholders' equity | 70,861 | 116,172 |
Total liabilities and shareholders' equity | $ 87,737 | $ 123,721 |